{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:17:01Z","timestamp":1791303421217,"version":"4.1.0"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To determine the frequency of laboratory abnormalities with methotrexate (MTX) use in patients with juvenile idiopathic arthritis (JIA); to identify potential risk factors for MTX toxicity requiring medical interventions; and to compare the frequency of liver function abnormalities in patients treated with MTX to those not treated with MTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Results of MTX surveillance laboratory testing (SLT) available in clinical databases were reviewed for 588 children with JIA. Information on demographics, JIA features, and factors previously associated with increased frequency of SLT abnormalities was obtained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Results of SLT performed in at least 4-month intervals were available for 138 JIA patients whose JIA was not treated with MTX, and for 198 JIA patients treated with MTX plus folic acid. On SLT of the MTX-treated patients, there were 44 of 2650 (1.7%) AST tests and 90 of 2647 (3.4%) ALT tests that exceeded 2 times the upper limit of normal (&gt; 2 ULN) in 30 children (15%). AST or ALT tests at &gt; 2 ULN occurred more often with systemic JIA (p = 0.04), macrophage activation syndrome, during infections, in systemic antibiotic use, and after intensifying JIA drug regimens. AST or ALT results at &gt; 2 ULN were as frequent among MTX-treated children as those not treated with MTX. Renal and hematological abnormalities with MTX were uncommon.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Liver enzyme abnormalities &gt; 2 ULN are rare in JIA, irrespective of MTX exposure. These data suggest that the adult standard of SLT every 4\u20138 weeks may not be necessary in children treated with MTX, especially if certain risk factors are absent.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090482","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T03:20:20Z","timestamp":1258428020000},"page":"2813-2818","source":"Crossref","is-referenced-by-count":33,"title":["Monitoring Methotrexate Toxicity in Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"36","author":[{"given":"LAKSHMI","family":"KOCHARLA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JANALEE","family":"TAYLOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TRACEY","family":"WEILER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TRACY V.","family":"TING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL","family":"LUGGEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HERMINE I.","family":"BRUNNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2009,11,16]]},"reference":[{"key":"2018112909213654000_36.12.2813.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20278"},{"key":"2018112909213654000_36.12.2813.2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.1780290703","article-title":"Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/anr.1780320202","article-title":"Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples","volume":"32","author":"Kremer","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/anr.1780321214","article-title":"Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy","volume":"32","author":"Weinblatt","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4615-4857-7_55","article-title":"Toxicity profile of methotrexate in rheumatoid arthritis. A preliminary survey","volume":"455","author":"Coleiro","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"2018112909213654000_36.12.2813.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80923-0"},{"key":"2018112909213654000_36.12.2813.9","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.1780401218","article-title":"The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis","volume":"40","author":"Hashkes","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.10","first-page":"846","article-title":"Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis","volume":"17","author":"Keim","year":"1990","journal-title":"J Rheumatol"},{"key":"2018112909213654000_36.12.2813.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70448-1"},{"key":"2018112909213654000_36.12.2813.12","first-page":"2442","article-title":"Hepatotoxicity in patients with juvenile idiopathic arthritis receiving long-term methotrexate therapy","volume":"29","author":"Lahdenne","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909213654000_36.12.2813.13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/anr.1780320604","article-title":"Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis","volume":"32","author":"Wallace","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.14","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909213654000_36.12.2813.15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/art.1780290616","article-title":"Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study","volume":"29","author":"Truckenbrodt","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2018112909213654000_36.12.2813.16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u00e2\u0080\u0099s Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"2018112909213654000_36.12.2813.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.20288"},{"key":"2018112909213654000_36.12.2813.18","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F"},{"key":"2018112909213654000_36.12.2813.19","first-page":"2501","article-title":"Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis","volume":"31","author":"Ortiz-Alvarez","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909213654000_36.12.2813.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(98)80018-6"},{"key":"2018112909213654000_36.12.2813.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.008441"},{"key":"2018112909213654000_36.12.2813.22","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200110000-00008"},{"key":"2018112909213654000_36.12.2813.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:37:21Z","timestamp":1543513041000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,16]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.3899\/jrheum.090482"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090482","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,16]]}}}